List of Tables
Table 1. Global Late-Stage Oncology Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Late-Stage Oncology Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Late-Stage Oncology Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Late-Stage Oncology Drug Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Late-Stage Oncology Drug Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Late-Stage Oncology Drug Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (kg)
Table 7. Global Late-Stage Oncology Drug Sales by Region (2020-2025) & (kg)
Table 8. Global Late-Stage Oncology Drug Sales by Region (2026-2031) & (kg)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Late-Stage Oncology Drug Sales by Manufacturers (2020-2025) & (kg)
Table 11. Global Late-Stage Oncology Drug Sales Share by Manufacturers (2020-2025)
Table 12. Global Late-Stage Oncology Drug Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Late-Stage Oncology Drug Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Late-Stage Oncology Drug by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Late-Stage Oncology Drug as of 2024)
Table 16. Global Late-Stage Oncology Drug Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Late-Stage Oncology Drug Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/g)
Table 18. Key Manufacturers Late-Stage Oncology Drug Manufacturing Base and Headquarters
Table 19. Global Late-Stage Oncology Drug Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Late-Stage Oncology Drug Sales by Type (2020-2025) & (kg)
Table 23. Global Late-Stage Oncology Drug Sales by Type (2026-2031) & (kg)
Table 24. Global Late-Stage Oncology Drug Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Late-Stage Oncology Drug Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Late-Stage Oncology Drug ASP by Type (2020-2031) & (US$/g)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Late-Stage Oncology Drug Sales by Application (2020-2025) & (kg)
Table 29. Global Late-Stage Oncology Drug Sales by Application (2026-2031) & (kg)
Table 30. Late-Stage Oncology Drug High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Late-Stage Oncology Drug Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Late-Stage Oncology Drug Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Late-Stage Oncology Drug ASP by Application (2020-2031) & (US$/g)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Late-Stage Oncology Drug Growth Accelerators and Market Barriers
Table 37. North America Late-Stage Oncology Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Late-Stage Oncology Drug Sales (kg) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Late-Stage Oncology Drug Growth Accelerators and Market Barriers
Table 40. Europe Late-Stage Oncology Drug Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Late-Stage Oncology Drug Sales (kg) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Late-Stage Oncology Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Late-Stage Oncology Drug Sales (kg) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Late-Stage Oncology Drug Growth Accelerators and Market Barriers
Table 45. Southeast Asia Late-Stage Oncology Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Late-Stage Oncology Drug Investment Opportunities and Key Challenges
Table 47. Central and South America Late-Stage Oncology Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Late-Stage Oncology Drug Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Late-Stage Oncology Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Roche Corporation Information
Table 51. Roche Description and Major Businesses
Table 52. Roche Product Models, Descriptions and Specifications
Table 53. Roche Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 54. Roche Sales Value Proportion by Product in 2024
Table 55. Roche Sales Value Proportion by Application in 2024
Table 56. Roche Sales Value Proportion by Geographic Area in 2024
Table 57. Roche Late-Stage Oncology Drug SWOT Analysis
Table 58. Roche Recent Developments
Table 59. Merck & Co Corporation Information
Table 60. Merck & Co Description and Major Businesses
Table 61. Merck & Co Product Models, Descriptions and Specifications
Table 62. Merck & Co Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 63. Merck & Co Sales Value Proportion by Product in 2024
Table 64. Merck & Co Sales Value Proportion by Application in 2024
Table 65. Merck & Co Sales Value Proportion by Geographic Area in 2024
Table 66. Merck & Co Late-Stage Oncology Drug SWOT Analysis
Table 67. Merck & Co Recent Developments
Table 68. Bristol Myers Corporation Information
Table 69. Bristol Myers Description and Major Businesses
Table 70. Bristol Myers Product Models, Descriptions and Specifications
Table 71. Bristol Myers Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 72. Bristol Myers Sales Value Proportion by Product in 2024
Table 73. Bristol Myers Sales Value Proportion by Application in 2024
Table 74. Bristol Myers Sales Value Proportion by Geographic Area in 2024
Table 75. Bristol Myers Late-Stage Oncology Drug SWOT Analysis
Table 76. Bristol Myers Recent Developments
Table 77. Pfizer Corporation Information
Table 78. Pfizer Description and Major Businesses
Table 79. Pfizer Product Models, Descriptions and Specifications
Table 80. Pfizer Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 81. Pfizer Sales Value Proportion by Product in 2024
Table 82. Pfizer Sales Value Proportion by Application in 2024
Table 83. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 84. Pfizer Late-Stage Oncology Drug SWOT Analysis
Table 85. Pfizer Recent Developments
Table 86. Novartis Corporation Information
Table 87. Novartis Description and Major Businesses
Table 88. Novartis Product Models, Descriptions and Specifications
Table 89. Novartis Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 90. Novartis Sales Value Proportion by Product in 2024
Table 91. Novartis Sales Value Proportion by Application in 2024
Table 92. Novartis Sales Value Proportion by Geographic Area in 2024
Table 93. Novartis Late-Stage Oncology Drug SWOT Analysis
Table 94. Novartis Recent Developments
Table 95. AstraZeneca Corporation Information
Table 96. AstraZeneca Description and Major Businesses
Table 97. AstraZeneca Product Models, Descriptions and Specifications
Table 98. AstraZeneca Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 99. AstraZeneca Recent Developments
Table 100. Johnson & Johnson Corporation Information
Table 101. Johnson & Johnson Description and Major Businesses
Table 102. Johnson & Johnson Product Models, Descriptions and Specifications
Table 103. Johnson & Johnson Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 104. Johnson & Johnson Recent Developments
Table 105. Eli Lilly and Company Corporation Information
Table 106. Eli Lilly and Company Description and Major Businesses
Table 107. Eli Lilly and Company Product Models, Descriptions and Specifications
Table 108. Eli Lilly and Company Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 109. Eli Lilly and Company Recent Developments
Table 110. Sanofi Corporation Information
Table 111. Sanofi Description and Major Businesses
Table 112. Sanofi Product Models, Descriptions and Specifications
Table 113. Sanofi Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 114. Sanofi Recent Developments
Table 115. AbbVie Corporation Information
Table 116. AbbVie Description and Major Businesses
Table 117. AbbVie Product Models, Descriptions and Specifications
Table 118. AbbVie Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 119. AbbVie Recent Developments
Table 120. GSK Corporation Information
Table 121. GSK Description and Major Businesses
Table 122. GSK Product Models, Descriptions and Specifications
Table 123. GSK Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 124. GSK Recent Developments
Table 125. Amgen Corporation Information
Table 126. Amgen Description and Major Businesses
Table 127. Amgen Product Models, Descriptions and Specifications
Table 128. Amgen Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 129. Amgen Recent Developments
Table 130. Genentech Corporation Information
Table 131. Genentech Description and Major Businesses
Table 132. Genentech Product Models, Descriptions and Specifications
Table 133. Genentech Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 134. Genentech Recent Developments
Table 135. Daiichi Sankyo Group Corporation Information
Table 136. Daiichi Sankyo Group Description and Major Businesses
Table 137. Daiichi Sankyo Group Product Models, Descriptions and Specifications
Table 138. Daiichi Sankyo Group Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 139. Daiichi Sankyo Group Recent Developments
Table 140. Aveo Oncology Corporation Information
Table 141. Aveo Oncology Description and Major Businesses
Table 142. Aveo Oncology Product Models, Descriptions and Specifications
Table 143. Aveo Oncology Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 144. Aveo Oncology Recent Developments
Table 145. Key Raw Materials Distribution
Table 146. Raw Materials Key Suppliers
Table 147. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 148. Milestones in Production Technology Evolution
Table 149. Distributors List
Table 150. Market Trends and Market Evolution
Table 151. Market Drivers and Opportunities
Table 152. Market Challenges, Risks, and Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Late-Stage Oncology Drug Product Picture
Figure 2. Global Late-Stage Oncology Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Chemotherapy Product Picture
Figure 4. Targeted Therapy Product Picture
Figure 5. Immunotherapy Product Picture
Figure 6. Hormonal Therapy Product Picture
Figure 7. Others Product Picture
Figure 8. Global Late-Stage Oncology Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Blood Cancer
Figure 10. Breast Cancer
Figure 11. Gastrointestinal Cancer
Figure 12. Prostate Cancer
Figure 13. Respiratory or Lung Cancer
Figure 14. Other
Figure 15. Late-Stage Oncology Drug Report Years Considered
Figure 16. Global Late-Stage Oncology Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 18. Global Late-Stage Oncology Drug Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 19. Global Late-Stage Oncology Drug Revenue Market Share by Region (2020-2031)
Figure 20. Global Late-Stage Oncology Drug Sales (2020-2031) & (kg)
Figure 21. Global Late-Stage Oncology Drug Sales (CAGR) by Region (2020-2031) (kg)
Figure 22. Global Late-Stage Oncology Drug Sales Market Share by Region (2020-2031)
Figure 23. Top 5 and Top 10 Manufacturers Late-Stage Oncology Drug Sales Volume Market Share in 2024
Figure 24. Global Late-Stage Oncology Drug Revenue Market Share Ranking (2024)
Figure 25. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 26. Chemotherapy Revenue Market Share by Manufacturer in 2024
Figure 27. Targeted Therapy Revenue Market Share by Manufacturer in 2024
Figure 28. Immunotherapy Revenue Market Share by Manufacturer in 2024
Figure 29. Hormonal Therapy Revenue Market Share by Manufacturer in 2024
Figure 30. Others Revenue Market Share by Manufacturer in 2024
Figure 31. Global Late-Stage Oncology Drug Sales Market Share by Type (2020-2031)
Figure 32. Global Late-Stage Oncology Drug Revenue Market Share by Type (2020-2031)
Figure 33. Global Late-Stage Oncology Drug Sales Market Share by Application (2020-2031)
Figure 34. Global Late-Stage Oncology Drug Revenue Market Share by Application (2020-2031)
Figure 35. North America Late-Stage Oncology Drug Sales YoY (2020-2031) & (kg)
Figure 36. North America Late-Stage Oncology Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 37. North America Top 5 Manufacturers Late-Stage Oncology Drug Sales Revenue (US$ Million) in 2024
Figure 38. North America Late-Stage Oncology Drug Sales Volume (kg) by Type (2020- 2031)
Figure 39. North America Late-Stage Oncology Drug Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 40. North America Late-Stage Oncology Drug Sales Volume (kg) by Application (2020-2031)
Figure 41. North America Late-Stage Oncology Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 42. US Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 43. Canada Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 44. Mexico Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 45. Europe Late-Stage Oncology Drug Sales YoY (2020-2031) & (kg)
Figure 46. Europe Late-Stage Oncology Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 47. Europe Top 5 Manufacturers Late-Stage Oncology Drug Sales Revenue (US$ Million) in 2024
Figure 48. Europe Late-Stage Oncology Drug Sales Volume (kg) by Type (2020-2031)
Figure 49. Europe Late-Stage Oncology Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 50. Europe Late-Stage Oncology Drug Sales Volume (kg) by Application (2020-2031)
Figure 51. Europe Late-Stage Oncology Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 52. Germany Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 53. France Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 54. U.K. Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 55. Italy Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 56. Russia Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 57. Asia-Pacific Late-Stage Oncology Drug Sales YoY (2020-2031) & (kg)
Figure 58. Asia-Pacific Late-Stage Oncology Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Asia-Pacific Top 8 Manufacturers Late-Stage Oncology Drug Sales Revenue (US$ Million) in 2024
Figure 60. Asia-Pacific Late-Stage Oncology Drug Sales Volume (kg) by Type (2020- 2031)
Figure 61. Asia-Pacific Late-Stage Oncology Drug Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 62. Asia-Pacific Late-Stage Oncology Drug Sales Volume (kg) by Application (2020-2031)
Figure 63. Asia-Pacific Late-Stage Oncology Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 64. Indonesia Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 65. Japan Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 66. South Korea Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 67. China Taiwan Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 68. India Late-Stage Oncology Drug Revenue (2020-2031) & (US$ Million)
Figure 69. Central and South America Late-Stage Oncology Drug Sales YoY (2020-2031) & (kg)
Figure 70. Central and South America Late-Stage Oncology Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Central and South America Top 5 Manufacturers Late-Stage Oncology Drug Sales Revenue (US$ Million) in 2024
Figure 72. Central and South America Late-Stage Oncology Drug Sales Volume (kg) by Type (2021-2031)
Figure 73. Central and South America Late-Stage Oncology Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Central and South America Late-Stage Oncology Drug Sales Volume (kg) by Application (2020-2031)
Figure 75. Central and South America Late-Stage Oncology Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. Brazil Late-Stage Oncology Drug Revenue (2020-2025) & (US$ Million)
Figure 77. Argentina Late-Stage Oncology Drug Revenue (2020-2025) & (US$ Million)
Figure 78. Middle East, and Africa Late-Stage Oncology Drug Sales YoY (2020-2031) & (kg)
Figure 79. Middle East and Africa Late-Stage Oncology Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 80. Middle East and Africa Top 5 Manufacturers Late-Stage Oncology Drug Sales Revenue (US$ Million) in 2024
Figure 81. Middle East and Africa Late-Stage Oncology Drug Sales Volume (kg) by Type (2021-2031)
Figure 82. South America Late-Stage Oncology Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 83. Middle East and Africa Late-Stage Oncology Drug Sales Volume (kg) by Application (2020-2031)
Figure 84. Middle East and Africa Late-Stage Oncology Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 85. GCC Countries Late-Stage Oncology Drug Revenue (2020-2025) & (US$ Million)
Figure 86. Turkey Late-Stage Oncology Drug Revenue (2020-2025) & (US$ Million)
Figure 87. Egypt Late-Stage Oncology Drug Revenue (2020-2025) & (US$ Million)
Figure 88. South Africa Late-Stage Oncology Drug Revenue (2020-2025) & (US$ Million)
Figure 89. Late-Stage Oncology Drug Industry Chain Mapping
Figure 90. Regional Late-Stage Oncology Drug Manufacturing Base Distribution (%)
Figure 91. Global Late-Stage Oncology Drug Production Market Share by Region (2020-2031)
Figure 92. Late-Stage Oncology Drug Production Process
Figure 93. Regional Late-Stage Oncology Drug Production Cost Structure
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed
